Skip to main content
REGN
NASDAQ Life Sciences

Regeneron's Lynozyfic Shows 100% Complete Response in AL Amyloidosis Trial

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$642.295
Mkt Cap
$67.369B
52W Low
$476.487
52W High
$821.11
52W Position info
35% above low
Off High info
22% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

REGN sits 35% above its 52-week low of $476.487.

Summary

Regeneron's Lynozyfic monotherapy achieved a 100% hematologic complete response rate in patients with second-line-plus systemic AL amyloidosis during a Phase 1/2 trial. This rare and fatal disease currently lacks approved therapies after initial treatment failure. The trial also showed significant improvement in renal and cardiac organ function for a majority of patients. These exceptionally strong results de-risk the drug for this new indication, representing a material pipeline win for Regeneron. This follows a consistent stream of positive drug development news for the company. Detailed results will be presented at ASCO on May 29.

At the time of this announcement, REGN was trading at $642.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.4B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

REGN - Latest Insights

REGN
Nov 18, 2026, 6:06 PM EST
Source: Reuters
Importance Score:
9
Price at Filing: $942.00
Real-time Price: $920.59 info
Change: -$21.41 (-2%) info
Market Cap: $95.228B info
REGN
Nov 08, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $900.00
Real-time Price: $920.59 info
Change: +$20.59 (+2%) info
Market Cap: $95.228B info
REGN
Oct 30, 2026, 12:34 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $910.52
Real-time Price: $920.59 info
Change: +$10.07 (+1%) info
Market Cap: $95.228B info
REGN
Oct 30, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $856.00
Real-time Price: $920.59 info
Change: +$64.59 (+8%) info
Market Cap: $95.228B info
REGN
Oct 30, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $835.00
Real-time Price: $920.59 info
Change: +$85.59 (+10%) info
Market Cap: $95.228B info